'מערכת אימד'Buisson et.al.; Clinical Gastroenterology and Hepatology 2023 Aug;21(9):2338-2346
Abstract
Background and aims: We assessed the effectiveness of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel diseases (IBDs) treated with or without intensified intravenous regimen.
Buisson A, Nachury M, Reymond M, Yzet C, Wils P, Payen L, Laugie M, Manlay L, Mathieu N, Pereira B, Fumery M. Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study. Clin Gastroenterol Hepatol. 2023 Aug;21(9):2338-2346.e3. doi: 10.1016/j.cgh.2022.08.011. Epub 2022 Aug 17. PMID: 35987302.